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Abstract
Background: Head and neck cancer survivors commonly experience severe long-term toxicities, late-occurring
symptoms, and significant risks of the second primary malignancy and comorbid illnesses. With multiple simultaneous
health issues, these complex cancer survivors often do not receive comprehensive health care that addresses their
needs. A tool is needed to streamline and standardize comprehensive care for this cohort.
Methods/design: We designed the Head and Neck Survivorship Tool: Assessment and Recommendations
(HN-STAR) to address health care challenges for head and neck cancer survivors. HN-STAR is an electronic
platform that aims to simplify the provision of personalized care in cancer survivorship clinics. It uses an
algorithmic approach to integrate patient-reported outcomes, clinical details, and evidence-based guidelines
to standardize comprehensive care provided in routine survivorship visits. It has four integrated components:
(1) a simplified treatment summary, which pulls treatment details from a clinical database or can be completed
manually using a streamlined form; (2) an online self-assessment for patients to report their own symptoms; (3) an
interactive discussion guide presenting all relevant information to the provider during the clinic visit; and (4) a
survivorship care plan generated at the end of each visit that reflects decisions made during the visit. By using a
modifiable electronic platform, HN-STAR provides a method for incorporating survivorship care plans into clinical
practice and for disseminating evidence on symptom management and preventive care.
This is a study to assess the feasibility of a future multi-site, randomized clinical trial of HN-STAR. We will enroll
head and neck cancer survivors who are followed in one of two nurse practitioner-led survivorship clinics. We will
implement HN-STAR for one routine survivorship visits. We will assess (1) usability and feasibility outcomes of HN-STAR
from the perspective of key stakeholders and (2) the planned outcomes intended for the larger trial. We will collect
usability and feasibility data from online surveys of survivors and their providers. Our findings will inform whether it is
feasible to advance HN-STAR to trial. If so, we will adapt HN-STAR and the study design of the trial in response to
feedback from survivors and providers. The long-term goal is to determine if such an intervention will lead to
improved and simplified comprehensive survivorship care.
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Discussion: This feasibility study will evaluate implementation of HN-STAR into clinical practice in terms of usability,
practicality, and clinical flow in two distinct clinical settings. This study will also provide critical baseline data to
characterize this vulnerable population. Findings from this study will inform a multicenter randomized trial of HN-STAR,
aimed at standardizing and streamlining the delivery of evidence-guided comprehensive care for head and neck
cancer survivors. Ultimately, if found effective, the modular structure of HN-STAR could permit its expansion to survivors
of other complex cancers.
Trial registration: ClinicalTrials.gov, NCT02571673
Keywords: Head and neck cancer, Survivorship, Patient-reported outcomes
Background
After cancer treatment is complete, cancer survivors
need a new approach to their ongoing care. Comprehen-
sive survivorship care involves routine surveillance for
recurrence and new cancers, detection and management
of chronic and late-developing toxicity (together called
“late effects”), and management of comorbid conditions.
For some survivors, the risks of recurrence and late ef-
fects are low, and a primary care provider can effectively
oversee comprehensive survivorship care with minimal
involvement of oncology providers. Other groups of
cancer survivors, however, have more complex needs
and require continued follow-up with their oncology
providers [1].
Head and neck cancer patients are one such group of
complex cancer survivors who confront numerous and
serious health challenges beyond the risk of local recur-
rence. Advances in treatment, specifically concurrent ra-
diation and chemotherapy, have improved survival in
head and neck cancer but have also led to an increase in
chronic and late-developing toxicity (late effects) [2–7].
Some common late effects include hearing loss, dry
mouth, decreased taste, neck fibrosis, and lymphedema
in the neck and face [8–11]. More debilitating late ef-
fects include destruction of the jaw, inability to speak,
difficulty swallowing, and difficulty opening the mouth
[12–16]. Up to half of head and neck cancer survivors
are diagnosed with psychological distress [17–19].
Because many head and neck cancers arise in the set-
ting of chronic tobacco or alcohol exposure, these pa-
tients also often have other tobacco-related comorbid
illnesses, such as other cancers, pulmonary disease, and
cardiovascular disease, and can have multiple non-
cancer health care providers [20–26].
With such complex needs, comprehensive survivor-
ship care may be difficult to deliver. The central focus of
survivorship care in head and neck cancer is early identi-
fication of recurrent and second head and neck cancers
by an oncology provider [1]. Although surveillance by
oncology providers also includes the identification and
management of late effects, there is no central clearing-
house for guidelines or standards in head and neck
cancer, suggesting that methods for addressing late ef-
fects likely vary by provider or by clinical practice.
Beyond oncologic surveillance, management of non-
oncologic care is necessary to improve survival. Primary
care should include aggressive management of comorbid
illnesses, risk modification (e.g., tobacco cessation), com-
pletion of recommended cancer screening for new (non-
head and neck) cancers, vaccination, and receipt of
general preventive care [21, 27]. Unfortunately, in two
studies, between 18 and 50 % of head and neck cancer sur-
vivors reported ever seeing a primary care provider [28, 29].
The failure to receive primary care has been documented
among survivors of other cancers [30–32]. In turn, cancer
survivors who do not receive primary care are less likely to
receive preventive services and appropriate interventions
for comorbidities than those who do [30, 31, 33–36].
Addressing multiple medical issues simultaneously, and
identifying which provider is responsible for management,
can complicate a cancer survivor’s ongoing care. In its
landmark report, From Cancer Patient to Cancer Survivor:
Lost in Transition, the Institute of Medicine (IOM) rec-
ommended the use of survivorship care plans to facilitate
coordination of survivorship care between oncology and
primary care providers [37]. A survivorship care plan is a
document given to the patient by oncology providers at
the end of treatment that includes (1) a treatment sum-
mary and (2) a plan of care describing late effects and rec-
ommendations for interventions and self-management
[37]. The survivorship care plan, which is shared with the
primary care provider, includes explicit plans for who is
responsible for each aspect of care. Survivorship experts
have widely endorsed the use of survivorship care plans,
and multiple professional societies have encouraged their
use [38–45]. However, the development and consistent
implementation of survivorship care plans in clinical prac-
tice have been challenging [46–52]. The major barriers to
the use of survivorship care plans are the time and
personnel required to create them and the difficulty
reviewing their content during routine visits [46–50, 52].
These barriers may be particularly problematic for com-
plex cancer survivors, like head and neck cancer survivors,
who may have multimodality treatment histories, have
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treatment-based surveillance recommendations, experi-
ence numerous persistent toxicities, be at risk for late
effects, require management of comorbidities, and need
modification of multiple risk factors—all of which should
to be noted in survivorship care plans.
We developed a web-based, algorithm-driven platform
called the Head and Neck Survivorship Tool: Assess-
ment and Recommendations (HN-STAR) to address the
most salient issues in providing comprehensive survivor-
ship care to head and neck cancer survivors. First, HN-
STAR ensures the identification of all late effects by
collecting symptom data directly from patients. It then
synthesizes patient-reported outcomes, treatment data,
and current evidence about survivorship care into a tai-
lored interactive discussion guide. The oncology pro-
vider uses the interactive discussion guide in a routine
oncology follow-up visit to address all elements of com-
prehensive survivorship care. Finally, HN-STAR auto-
matically creates the survivorship care plan based on the
clinic visit, which minimizes burden for oncology pro-
viders. This survivorship care plan can be updated at
each visit to incorporate symptom changes, modified
management plans, and more current evidence regard-
ing survivorship care (Fig. 1).
The goal of our protocol is to evaluate the feasibility of
HN-STAR in the setting of survivorship clinics, in prepar-
ation for a future multi-site randomized controlled trial.
The future trial will randomize clinics at multiple centers
to use HN-STAR or usual care, and the primary trial out-
comes will be changes in (1) the number of late effects
identified and (2) the number of late effects managed in
clinic. We will also investigate adherence to recommended
care and any changes in health outcomes.
The current protocol is a feasibility study to inform
preliminary outcomes, design, and sample size for the
future trial. Specifically, we are interested in usability of
our interface for patients and providers, feasibility of
study conduct (recruitment and completion), feasibility
of data collection using a web interface and medical rec-
ord abstraction, clinical and demographic features of our
study sample, and differences in our primary outcomes
before and after the intervention. These outcomes will
guide whether to advance HN-STAR to a randomized
clinical trial of its effectiveness. If HN-STAR will advance
to trial, we will use our findings to adapt HN-STAR and
the design of the trial.
Methods/design
Overview
The purpose of this study is to evaluate the feasibility of
HN-STAR as an intervention to streamline comprehen-
sive survivorship care for head and neck cancer survi-
vors in a randomized, multi-site clinical trial setting. We
will incorporate HN-STAR into a routine survivorship
clinic visit, in order to assess the use of HN-STAR in
clinical practice. Prior to a routine clinic visit, each patient
will report his or her medical history, preventive care, and
symptoms online using the survivor self-assessment. This
information (as well as other medical history information)
will populate an interactive discussion guide for the nurse
practitioner (NP) to use during the clinic visit. Decisions
regarding management will be recorded in HN-STAR to
generate the survivorship care plan. Each patient and his
or her primary care provider (PCP) will receive the auto-
matically generated survivorship care plan. We will assess
feasibility outcomes from the patient, his or her NP,
and his or her primary care provider. We will also
abstract key information from the medical record on
clinical outcomes.
Eligibility and recruitment
Head and neck cancer survivors
Eligible patients must be scheduled to receive routine
follow-up in the survivorship clinics at Memorial Sloan
Kettering Cancer Center (MSK) and Hartford Hospital
(HH). In order to be seen at the clinics, they must (1)
Fig. 1 HN-STAR components and clinical flow
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have completed treatment for head and neck cancer at
least 1 year prior to survivorship visit, (2) have no evi-
dence of disease, (3) have a primary care provider on
record, and (4) be at least 18 years old. To be eligible for
the study, they must be able to provide informed con-
sent and be able to speak and read English. Patients
with cognitive, visual, or motor impairment such that
they cannot complete the survivor self-assessment (as
assessed by the research team) will be excluded.
Two weeks before each patient’s scheduled survivor-
ship clinic visit at either MSK or HH, eligible head and
neck cancer survivors will be invited by mail to partici-
pate in the HN-STAR study. Patients will provide
informed consent over the phone with the research
assistant, in accordance with MSK IRB #15-245 (Clini-
caltrials.gov number: NCT02571673). The patient will
complete the survivor self-assessment on a laptop or
tablet before the clinic visit (at home or in the waiting
room).
Primary care providers
After a participant has attended the survivorship clinic
visit and received the survivorship care plan, their identi-
fied PCP will be mailed the survivorship care plan. One
week later, at each site, the research assistant will con-
tact the PCP associated with the participant by mail and
follow up by telephone to invite them to complete an
online survey. Through the consent process, participants
will be informed that their PCP will be surveyed and
interviewed about HN-STAR as part of the study.
Nurse practitioners
We will ask the two NPs to provide feedback (via
surveys and interview) about their experiences using
HN-STAR. Through the consent process, participants
will understand that their NP will be surveyed and
interviewed about HN-STAR as part of the study.
Usual care setting
We will implement HN-STAR in routine follow-up visits
in two survivorship clinics—the Head and Neck Sur-
vivorship Clinic at MSK and the clinic of Gray Cancer
Center’s Survivorship Program at HH. The two separate
sites will allow us to investigate HN-STAR with the elec-
tronic access of claim data (MSK) and without (HH), to
inform the scalability of HN-STAR. Each clinic is led by
a single NP. The head and neck survivors seen in each
clinic have completed treatment for head and neck can-
cer at least 1 year prior and have no evidence of disease.
In standard care, the NP provides oncologic follow-up,
creates and delivers a survivorship care plan, addresses
healthy behaviors, and ensures that the survivor has a
primary care provider who will manage general preventive
care. At MSK, the NP continues to follow the survivor
annually; at HH, the NP provides a one-time consultative
visit before the survivor continues to visit their oncologist.
Intervention
HN-STAR has four components, described below.
Survivor self-assessment
The HN-STAR survivor self-assessment includes vali-
dated items whenever possible. First, the survivor self-
assessment elicits the presence and burden of toxicities
using relevant items from the National Cancer Institute’s
Patient-Reported Outcomes version of the Common
Terminology Criteria for Adverse Events (PRO-CTCAE)
[53]. For symptoms that are specific to head and neck
cancer but not included in existing PRO-CTCAE mea-
sures, we have created items using the same format and
symptom attributes as existing items. These symptoms
are bleeding from the mouth, trismus, hearing loss, jaw
pain, neck or shoulder stiffness, neck pain, pain with
swallowing, and bad breath. In addition, the survivor
self-assessment includes items regarding medical history
and preventive health. Items from validated screening
instruments are used to identify alcoholism, tobacco use,
physical activity, sexual function, and depression, as
shown in Table 1 [54–58]. For other health behaviors, ad
hoc assessments are based upon guidelines and institu-
tional consensus at MSK and HH [59–66]. Patients fill
out the survivor self-assessment online before the visit,
either at home or in the clinic waiting room.
Treatment checklist
The treatment checklist uses claim data from the head
and neck cancer diagnosis and treatment. The technical
terms will then be translated into lay language. This will
be done differently at the two participating sites.
1. At MSK, we will incorporate the electronic claim
data into our platform. HN-STAR generates an
Automated Treatment Checklist, which presents
an organized list of diagnosis, staging, and treatment
received at MSK using claim data from billing codes
in the MSK record. The NP is prompted to verify the
accuracy of the presented list and make necessary
corrections.
2. At HH, where claim data will not be automatically
ported to HN-STAR, there is a Manual Treatment
Checklist, in which all possible diagnosis and
treatment options are presented as an organized
checklist. The NP must manually complete the
Manual Treatment Checklist by referring to the
patients’ medical records.
At either institution, once a patient has agreed to par-
ticipate in the study, prior to the participant’s
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survivorship clinic visit, the NP will verify or complete
the checklist. The checklist will result in the generation
of a lay language treatment summary that will appear in
the survivorship care plan (described below). The NPs at
both sites will be trained on how to use the treatment
checklist.
Interactive discussion guide
The interactive discussion guide integrates responses
from the survivor self-assessment, verified data from the
treatment checklist, and an evidence base for survivor-
ship care. Three algorithms will then use these data to
generate the interactive discussion guide that the NP can
use during the routine visit (Fig. 2).
1. Treatment algorithms use Current Procedural
Terminology (CPT) codes and National
Comprehensive Cancer Network (NCCN)
guidelines to generate personalized surveillance
recommendations (e.g., annual thyroid studies for
survivors who received radiation to neck) [1].
2. Symptom algorithms use PRO-CTCAE responses to
identify toxicities of treatment and other relevant
issues to address. In the interactive discussion guide,
seen only by the NP, these symptoms populate an
evidence-based list of common diagnosis to consider,
recommendations for focused evaluation, and
recommended management options. We have
developed these recommendations based on
existing evidence when available and institutional
consensus within MSK and approval from HH
otherwise. We will refine these guidelines as new
evidence emerges [40, 67–78].
3. Prevention algorithms use patient responses and
demographic information to generate a list of
personalized prevention recommendations, adapted
from the US Preventive Service Task Force and
NCCN survivorship guidelines [1, 59–66, 79–82].
Using the interactive discussion guide, the NP will
discuss ongoing care and select management plans
with the survivor. Selected symptom management
plans are entered into HN-STAR and populate the
survivorship care plan (described below).
The interactive discussion guide is intended only for
the NP to use during the clinic visit. The NP at each site
will be trained on how to use the interactive discussion
guide.
Survivorship care plan
Finally, the survivorship care plan will present a treat-
ment summary and plan of care. HN-STAR generates a
survivorship care plan after each visit. The treatment
summary contains a plain-language cancer history. The
plan of care contains personalized recommendations for
cancer surveillance, management of late effects, and pre-
ventive care, reflecting discussions and decisions from
the clinic visit. It also reports a list of non-cancer
Table 1 Standardized items in survivor self-assessment
Construct Source
Symptom: memory, insomnia, fatigue, tiredness, or lack of energy, numbness or
tingling in your hands or feet, shortness of breath, cough, ringing in your ears,
dry mouth, voice changes, nosebleeds, mouth or throat sores, pain (general),
difficulty swallowing, dizziness
Patient Reported Outcomes—Common Terminology Criteria for
Adverse Events [53]
Symptom: difficulty hearing, neck or shoulder stiffness, neck pain, jaw pain,
pain in your mouth, pain in your throat, frequency of pain (general), difficulty
with opening your mouth, bad breath, bleeding from your mouth
Based on Patient Reported Outcomes—Common Terminology
Criteria for Adverse Event
Symptom: sexual function The European Organization for Research and Treatment of Cancer
Quality of Life Questionnaire-C30—Head and Neck-35 [95]
Symptom: depression Patient Health Questionnaire-2 [55]
Physical activity: frequency Godin Leisure-Time Exercise Questionnaire [56]
Physical activity: average exercise time Adaptation of the Godin Leisure-Time Exercise Questionnaire [56]
Smoking status: at least 100 cigarettes in entire life National Health Interview Surveya
Smoking status to determine need for smoking cessation (ever smoked
cigarettes, smoking in the past 30 days)
National Comprehensive Cancer Network Smoking Cessation
Guidelinesb
Smoking status: years as a smoker cigarette exposure to determine eligibility
for lung cancer screening (cigarettes per day, time since quitting)
Lung Cancer Screening Decision Toolc
Smoking history and current status to determine need for smoking cessation
(ever smoked cigarettes, smoking in the past 30 days)
National Comprehensive Cancer Network Smoking Cessation
Guidelinesb
Alcohol alcoholism use The CAGE questionnaire [54]
aNational Health Interview Survey, Questionnaires, Datasets, and Related Documentation 1997 to the present, centers for disease control and prevention
bNCCN CLinical Practice Guidelines in Oncology, Smoking Cessation, Version 1.2015, 2015
cLung Cancer Screening Decision Tool, mskcc.org Prediction Tools, Memorial Sloan Kettering Cancer Center, 2014
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conditions reported by the patient. Each recommenda-
tion includes a schedule and clear delineation of who is
responsible. The plan of care also contains generic sur-
vivorship information, with a description of signs and
symptoms to report to the oncology provider, contact
information for the oncology provider, and recommen-
dations to visit a primary care provider.
Clinical flow using HN-STAR
We will test the feasibility of using HN-STAR over the
course of a single, routine survivorship visit at either
MSK or HH.
Before the survivorship visit: At MSK, the institutional
database of CPT codes will automatically populate the
Automated Treatment Checklist in HN-STAR, and the
NP will verify its accuracy against the medical record. At
HH, the NP will use the medical record to complete the
Manual Treatment Checklist. At both sites, the treat-
ment checklist will inform treatment-based recommen-
dations in the interactive discussion guide and generate
a plain-language treatment summary for the survivor-
ship care plan.
Before the survivorship visit: Survivors will complete
the online survivor self-assessment. Using the survivor
self-assessment and treatment checklist data, HN-STAR
will create the interactive discussion guide for the clinic
visit that presents (1) an oncologic surveillance schedule,
(2) a list of severity-based symptom management op-
tions, and (3) personalized preventive care and screening
recommendations.
Fig. 2 Excerpt of interactive discussion guide for insomnia
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During the visit: The NP will use the interactive dis-
cussion guide to facilitate conversation. Specifically, the
NP will conduct a physical exam, and the NP and sur-
vivor will discuss ongoing care, select plans for symptom
management, and identify who is responsible for each
action (NP, survivor, or primary care provider).
At the end of the visit: The treatment checklist will be
combined with the selected plan of care from the visit to
create a survivorship care plan. At the end of the visit,
the survivorship care plan will be printed, given to the
survivor and discussed with the survivor. The research
assistant will also offer to send a printer-friendly version
of the survivorship care plan to the survivor, if the sur-
vivor wishes to provide an email address. After the visit,
a printed version of the survivorship care plan will be
sent to each survivor’s primary care provider.
Study end points
This study uses surveys at multiple time points to elicit
feedback from patients, NPs, and PCPs regarding the use
of this system. In addition, to inform whether trial out-
comes can be feasibly collected, and to inform a pretest-
posttest analysis, we will collect from HN-STAR and the
medical record indicators of care received, to establish
baseline measures and inform feasibility of collecting data
for a future trial. A subset of these indicators will be col-
lected from medical records before and after the clinic
visit, using a pretest-posttest design. These end points are
described in more detail in the following sections.
Study end points from surveys
Surveys will collect data from each survivor, his or her NP,
and his or her PCP. All surveys are self-administered in
HN-STAR, and responses are recorded and stored elec-
tronically. Survey end points are described below and in
Table 2.
1. Survivor Post-Assessment Survey: After completing
the survivor self-assessment online, each survivor
will complete the Survivor Post-Assessment Survey
regarding perceptions of the survivor self-assessment
[83, 84].
2. Survivor Post-Visit Survey: When the patient comes
for the clinic visit, the research assistant will be at
the clinic and available to answer questions about
the study and direct the integration of study flow in
clinical practice as needed. Each patient will see the
NP (who will use the interactive discussion guide
during the visit) and receive the survivorship care
plan. The survivor will then complete the Survivor
Post-Visit Survey on a computer or iPad. The
Survivor Post-Visit Survey elicits participant opinion
on the clinic visit and the survivorship care plan
[83–86].
3. Primary Care Provider Survey: Two weeks after the
visit (when the survivorship care plan is mailed to
the PCP), each patients’ PCP will be invited to
complete a brief online survey regarding the
survivorship care plan [87–89].
4. Nurse Practitioner Post-Visit Survey: Directly after
each clinic visit, the NP will complete a brief online
survey regarding the experience of using the interactive
discussion guide during the visit [88–90].
5. Nurse Practitioner Interview: After all survivors have
completed feasibility testing, the research assistant
will conduct a qualitative interview with each NP to
evaluate the use of the interactive discussion guide
and creation of the survivorship care plan.
Study end points from HN-STAR and medical records
Survivor and nurse practitioner data will be recorded
through the web interfaces of HN-STAR. In addition,
NPs will document clinic notes as part of routine care,
as described below and in Table 2.
1. For all visits at MSK, preceding the patient visit, the
NP will verify the Automated Treatment Checklist.
When the NP makes any changes to imported data
and verifies the final treatment checklist, these
changes will be recorded and will inform the
accuracy of the automatically generated treatment
summary and the time required to verify the
information.
2. For all visits at HH, preceding the patient visit, the
NP will complete the Manual Treatment Checklist.
Data will be collected regarding the time required to
complete the checklist.
3. All patients will complete the survivor self-assessment
before their clinic visit. HN-STAR will record the
amount of time taken, the items skipped, and the
proportion of the self-assessment completed. In
addition, the survivor self-assessment records the
receipt of non-oncologic care, such as screening for
new cancers, vaccination, and other preventive care
elements that are explicitly collected in the survivor
self-assessment.
4. As part of routine care, the NP will record topics
addressed and actions taken for each visit (including
referrals, prescriptions, and other management
plans) in the clinic note as part of routine care. These
cancer-related, or oncologic, outcomes indicate care
received, and they include late effects (symptoms)
identified and addressed, receipt of head and neck
surveillance, and appropriate follow-up (e.g., dental
exam for those who underwent radiation therapy
and tobacco cessation referral for those who
smoke). Our primary oncologic outcomes are the
identification and management of late effects. For
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Table 2 Study end points




Patient Upon completion of survivor self-assessment, before the clinic visit • Perceptions of information quality, system quality, and usefulness, ease of use
Survivor Post-Visit Survey Patient Following clinic visit • Opinion on the usefulness of the survivor self-assessment in the clinic visit
• Ease of use of, satisfaction with, and perceived usefulness of the survivorship
care plan
Primary Care Provider Survey PCP One week after being mailed survivorship care plan, within a month
of enrollment into study
• Whether they received and reviewed the survivorship care plan




NP Following each clinic visit • Whether the interactive discussion guide presented a complete list of issues
for the patient
• Whether it contained irrelevant information
• Length of the visit
Nurse Practitioner Interview NP After all patients have completed clinic visits • Problems with and benefits of interactive discussion guide
• Whether the usefulness or usability of the interactive discussion guide varied by
type of patient seen in clinic
Non-survey metrics: HN-STAR
Automated Treatment Checklist MSK NP Immediate concurrent data collection before study visit • Accuracy of automatic treatment summary generation
• Time required to verify
Manual Treatment Checklist HH NP Immediate concurrent data collection before study visit • Time required to complete checklist
Survivor self-assessment Patient Immediate concurrent data collection before study visit • The amount of time taken
• The items skipped
• The proportion of the self-assessment completed
• Receipt of routine preventive care (including cancer screening tobacco cessation,
immunizations, and routine general testing)
Non-survey metrics: clinic note
NP Part of routine care, abstracted from any time in the year before the
visit (pretest) and in the note pertaining to the clinic visit (posttest)
• Late effects identified and addressed
• Receipt of head and neck surveillance
• Receipt of appropriate follow-up (e.g., smoking cessation, dental exam, blood work












each late effect assessed in HN-STAR, we will
consider it identified if it was mentioned in a clinic
note, and we will consider it addressed if there was
a referral, recommendation, education, or explicit
acknowledgement of inaction. (Inaction may be
appropriate, because in some cases, when symptoms
are persistent and intractable, no intervention may be
recommended.) Clinic note data will be used as part
of a pretest-posttest design, described in further detail
below. The research assistant at each site will retrieve
data regarding late effects identified and addressed in
the year preceding the study visit and during the study
visit, to assess changes before and after the HN-STAR
intervention. The research assistant will also assess
oncologic surveillance occurring in the year preceding
the study visit and during the study visit from
the medical record, using a medical record data
abstraction form.
Sample size
This feasibility study is not powered to test formal hy-
potheses, such as differences in end points by patient
characteristics. Instead, it will provide feedback regard-
ing, and outcomes from, the HN-STAR process. We will
recruit 45 patients: 30 from MSK and 15 from HH. This
sample size is likely adequate to reach thematic satur-
ation. We estimate that this sample size is feasible within
the two clinics and should provide variability between
survivors on factors such as age, gender, diagnosis, comor-
bidities, risk factors, and competency with computers.
Further, a sample size between 24 and 50 is recommended
for pilot studies to estimate sample sizes for a future
trial [91–93].
We will continue to enroll patients until 45 patients
reach the end of the survivor self-assessment. Patients
who skip items in the survivor self-assessment, who skip
items in the surveys, or who terminate a study visit early
will be included in the feasibility analysis, as these ac-
tions provide important feasibility data. However, any
patients who do not reach the last web page of the sur-
vivor self-assessment will be excluded from the study,
because the patient needs to reach the final web page of
the self-assessment (even if all items within it are
skipped) in order to create the interactive discussion
guide.
Analysis of feasibility metrics
The structured survey questions will be summarized
using descriptive statistics. We will calculate means and
standard deviations for continuous variables and counts
and percentages for categorical variables, presented with
95 % confidence intervals. Quantitative outcomes will
include survivors’ rates of completion of the self-
assessment and survey completion rates for survivor,
NP, and Primary Care Provider Surveys [94]. The
number of questions to answer is different between
surveys and between respondents, based on skip pat-
terns built into the electronic survey platform. Each
survey will be considered complete if at least 75 %
of questions that are asked are answered. Other
quantitative outcomes include survivors’ participation
rate (including clinical and demographic descriptors
of participants and non-participants as well as rea-
sons for non-participation), when the survivor self-
assessment was completed (indicating whether it was
at home or just prior to the visit), the median time
survivors required to complete the self-assessment,
the accuracy of the automated treatment summary
(verified against the EMR), the time required for NP
verification of the treatment summary, and the length of
HN-STAR visits.
Each component of HN-STAR will be evaluated indi-
vidually for feasibility. We will consider the survivor
self-assessment feasible for subsequent effectiveness test-
ing if the following benchmarks are met:
 >75 % survivors completed >75 % of the items
within the self-assessment.
 The mean proportion of assessment completed >75 %.
 The median time to complete self-assessment <15 min.
 >50 % of survivors rate the self-assessment visit
positively on the Survivor Post Assessment Survey.
We will consider the Automated Treatment Checklist
feasible if the following benchmarks are met:
 >90 % of the treatment summaries were deemed
accurate.
 The median time to verify the summary <20 min.
We will consider the Manual Treatment Checklist
feasible if the following benchmarks are met:
 The median time to complete <30 min. (In practice,
survivorship care plans typically take an hour or
more to complete [47]).
The interactive discussion guide will be considered
feasible if the following benchmarks are met:
 >75 % of interactive discussion guides did not miss
relevant information. We will determine whether
relevant information was covered using the Nurse
Practitioner Survey.
 >50 % of survivors rate the survivorship visit positively
on the Survivor Post Assessment Survey.
 The median visit time <50 min (current visit time
average is 40 min).
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The survivorship care plan will be deemed feasible if
the following criteria are met:
 >50 % of survivors rate the survivorship care plan
positively, as rated in the Survivor Post-Visit Survey.
 >50 % of primary care providers rate the survivorship
care plan positively in the Primary Care Provider
Survey.
If any component does not meet all criteria, we will
consider further adapting the component as needed and
testing them further in a future protocol.
Analysis of preliminary metrics of processes of care
We will use descriptive statistics to report receipt of
oncologic and non-oncologic care, as described below.
Oncologic outcomes
For receipt of appropriate cancer-related surveillance,
we will use descriptive statistics to report each element
of oncologic care that each patient received. Each patient
may not require every element of follow-up, depending
on their primary tumor site or treatment received. These
cancer-related elements of care may include a history
and physical, thyroid exam, recommendation to receive
a dental exam, and referral to tobacco cessation. We will
use the number of recommended elements of care
(based on survivor characteristics) as the denominator,
and we will calculate the proportion of these elements
that are performed as indicated in the clinic note. To
quantify the management of late effects, for each pa-
tient, we will first count the number of late effects iden-
tified in the survivor self-assessment. We will then
calculate the proportion of identified late effects that
are addressed.
We will calculate the difference in each oncologic out-
come before HN-STAR use and after. Differences in on-
cologic metrics will be used in the power calculation for
the proposed randomized trial. Any observed differences
may in part be due to performance bias, with the NP
being more attentive during a study visit, and will be
interpreted cautiously.
Non-oncologic outcomes
The non-oncologic outcomes (e.g., cancer screening and
vaccination) in HN-STAR are collected only once in the
survivor self-assessment, before the clinic visit. These
metrics will be reported descriptively to provide baseline
measures and inform the feasibility of collecting these
data from self-report. Only some of these elements will
be recommended for each patient, depending on the pa-
tient’s age, sex, and behaviors. We will determine the
number of recommended elements for each patient and
calculate the proportion of recommended elements of
non-oncologic care that are performed per patient prior
to the clinic visit. In addition, for each element of non-
oncologic care, we will determine the number of patients
for whom that element is recommended and calculate
the proportion of patients who received it as recom-
mended prior to the clinic visit.
Adaptation and advance of HN-STAR
If HN-STAR is deemed feasible for further effectiveness
testing, using the benchmarks described above, we will
use our findings to adapt the content of HN-STAR. Spe-
cifically, the recruitment rate will guide estimates of
timelines for clinical recruitment. Skipped items on the
survivor self-assessment and surveys will guide the revi-
sion and adaptation of these instruments. If needed, we
will consider assessing often-missing data elements from
other sources. Other feasibility data may inform how to
integrate HN-STAR into the clinical flow more effect-
ively or how to ease data collection for patients.
The primary outcomes of the future trial will be the
identification and management of a selection of the late
effects measured in HN-STAR. We will base the selec-
tion of late effects on prevalence, demonstration of
unmet needs, changes in how often a late effect is ad-
dressed between pretest and posttest, and feasibility of
measurement and data collection.
We will also use the baseline rates and pretest-posttest
changes in rates of the identification and management
of late effects to estimate the sample size for the
future trial.
We will then advance HN-STAR to a randomized clin-
ical trial to assess its effectiveness in improving the
health outcomes assessed in aim 2.
Discussion
This feasibility study will evaluate implementation of
HN-STAR into clinical practice in terms of usability,
practicality, and clinical flow. HN-STAR requires mul-
tiple changes to usual care, and we will use stakeholder
feedback to ease the implementation of HN-STAR in a
trial. Survivors will report how comfortable they are with
reporting their own symptoms online, having the nurse
practitioner use a computer in clinic to guide their care,
and receiving a survivorship care plan. For example,
based on patient feedback, we may improve the interface
of assessing symptoms or change the content or layout
of the survivorship care plan. NPs will report their own
comfort with creating a treatment summary and using a
computer during the clinical encounter and automatic-
ally generating a survivorship care plan. We may find,
for example, that the transition from the interactive dis-
cussion guide to the physical exam is unnatural, and we
will adapt the tool to integrate more seamlessly into the
clinical visit. PCPs will opine about the receipt and
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usefulness of the automatically generated survivorship
care plan. If, for example, PCPs find the survivorship
care plan too long, we may abbreviate the content. Re-
sponsiveness to stakeholder feedback will improve the
intervention for future users.
This study will also provide critical baseline data to
characterize this vulnerable population. Currently, little
is known about the prevalence of late effects and the un-
met late effect management needs among head and neck
cancer survivors. The presence and management of co-
morbid conditions have also not been well characterized.
Using the data from this feasibility study, a future trial
can help to target the most salient needs in this vulner-
able population.
HN-STAR must have the flexibility to function well in
multiple environments in order to be feasible in a clin-
ical trial. The two sites (MSK and HH) enable the as-
sessment of differences with and without direct EMR
integration of HN-STAR, informing the scalability of this
intervention. If we find, for example, that the NPs in the
two clinics provide conflicting feedback about how to
adapt the interactive discussion guide for use in the visit,
we may need to build more flexibility into HN-STAR so
that it can be used differently in different settings.
Findings from this study will inform a multicenter
randomized trial of HN-STAR, aimed at standardizing
and streamlining the delivery of evidence-guided com-
prehensive care for head and neck cancer survivors.
Ultimately, if found effective, the modular structure of
HN-STAR could permit its expansion to survivors of
other complex cancers.
Trial status
The trial has received IRB approval and began enrollment
in February 2016.
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